## IQV: IQVIA Holdings Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.96 indicates fundamental undervaluation. Quality metrics strong (ROE 19%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-4.3% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($212.72)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. IQVIA (IQV) Stock: Q3 2025 Results, 23% 3-Month Surge, and Analyst Outlook - News and Statistics**
- Source: IndexBox | 20251204T071117 | Bullish | Relevance: 100%
- IQVIA Holdings Inc. (IQV) is trading 3% below its 52-week high after reporting strong Q3 2025 financial results, with revenue up 5.2% and adjusted EPS up 5.6% year-over-year. The stock has surged 23.1% in the past three months, outperforming the S&P 500, and analysts have a "Strong Buy" consensus rating with a 7.4% upside potential.

**2. Is IQVIA Holdings Stock Outperforming the S&P 500?**
- Source: Markets Financial Content | 20251204T033200 | Bullish | Relevance: 100%
- IQVIA Holdings Inc. (IQV) has shown strong performance in the short term, with its stock soaring 23.1% over the past three months, outperforming the S&P 500's 6.2% gains. The company, valued at $38.4 billion, exceeded Q3 earnings expectations and boasts a "Strong Buy" consensus rating from analysts. While slightly lagging the broader market over longer periods, IQV demonstrates a bullish trend and significant upside potential.

**3. IQVIA (NYSE: IQV) names AWS preferred agentic cloud to power new AI platform**
- Source: Stock Titan | 20251202T080000 | Bullish | Relevance: 100%
- IQVIA (NYSE: IQV) announced a strategic collaboration with Amazon Web Services (AWS), naming AWS as its Preferred Agentic Cloud Provider. This partnership aims to revolutionize clinical trial automation, medical affairs, and analytics in life sciences by deploying IQVIA's AI platform on AWS. The collaboration seeks to democratize AI for life sciences, accelerate drug innovation, and improve patient outcomes globally.

**4. IQVIA Holdings stock rating assumed at Overweight by Morgan Stanley**
- Source: Investing.com India | 20251202T033600 | Bullish | Relevance: 100%
- Morgan Stanley has initiated coverage of IQVIA Holdings (NYSE:IQV) with an Overweight rating and a price target of $265.00, citing expected strong demand for clinical stage CRO work and the company's leading position in diversified end markets. This positive outlook is supported by a significant 63.91% price return over the past six months and aligns with other analyst upgrades, despite some valuation concerns.

**5. Is IQVIA Holdings Stock Outperforming the S&P 500?**
- Source: Barchart.com | 20251204T035407 | Bullish | Relevance: 100%
- IQVIA Holdings Inc. (IQV) is a large-cap company providing clinical research and healthcare intelligence. The stock has outperformed the S&P 500 over the past three months and analysts rate it a "Strong Buy." Despite lagging the broader market over the past year, IQVIA reported strong Q3 results, beating revenue and EPS expectations.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $265 | $250 | +6% |
| 2025-11-13 | BMO Capital | $260 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-11-13 | BMO Capital | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 2 ($4.59M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.3% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $4.6M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +6%). Insider selling cluster ($4.6M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.6B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.30 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 17.4 |
| Current P/E | 18.9 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.5% to -0.8% (-4.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.8pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: -SLH (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.77% (CS: 44) | Neutral |
| RSI_14 | 57.3 | Neutral |
| MACD Histogram | -0.27 | Bearish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 1.059x | Above |
| vs SMA200 | 1.247x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $224.92
- **Stop Loss:** $212.72 (5.4% risk)
- **Target:** $249.32 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 40
- **Position Value:** $8,996.80
- **Portfolio %:** 9.00%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*